Ibogaine for Opioid Addiction: Evidence, Trials, and Safety

Ibogaine for opioid addiction is the single indication where psychedelic medicine has produced its most consistent clinical signal. In observational programs across Mexico and Costa Rica, a single supervised dose has repeatedly interrupted physical dependence on heroin, oxycodone, and fentanyl within 24 to 36 hours — without the weeks or months of medication-assisted taper conventional treatment requires. Ibogaine for opiate addiction is what draws most patients to the substance in the first place.

That signal is why Texas committed $50 million in state money to ibogaine research in 2025, why Stanford ran the MISTIC trial, and why the FDA has authorized multiple ongoing INDs. It is also why cardiac safety has become the field's most-discussed question. This guide covers what the evidence actually shows, how patients access treatment today, and what a responsibly run session looks like.

Why ibogaine works differently for opioids

Ibogaine works differently from other addiction treatments because a single dose can interrupt opioid dependence for weeks. Where methadone and buprenorphine substitute one opioid for a longer-acting one, ibogaine appears to reset the reward circuitry itself. Its metabolite noribogaine has a half-life measured in days and continues acting long after the acute experience ends.

The pharmacology behind that reset is unusual and multi-target:

• NMDA antagonism — dampens the glutamate signaling that drives withdrawal hyperexcitability.
• Kappa-opioid agonism — modulates dysphoria and craving circuits mu-opioid drugs do not touch.
• Sigma-1 and serotonergic activity — contribute to the visionary phase and mood effects.
• Noribogaine's long half-life — sustains anti-craving effects for days to weeks after a single dose.
• Increased GDNF expression — glial-cell-line-derived neurotrophic factor supports dopaminergic recovery, hypothesized to underlie the durable anti-addictive effect.

Read the parent ibogaine guide for the full mechanism review, and the psychedelic therapy for addiction hub for how ibogaine compares to ketamine, psilocybin, and MDMA across substance-use indications.

The evidence: observational studies and controlled data

The clinical case for ibogaine in opioid use disorder rests on a decade of observational cohorts and a growing set of FDA-authorized studies. There is no completed Phase 3 randomized controlled trial yet — that gap is what the Texas IMPACT program is designed to close.

The most-cited datasets:

• Mash et al. 2018 (Frontiers in Pharmacology) — Freedom Centers observational cohort of 191 opioid and cocaine patients. 80% were relapse-free at one month, with sustained improvement in depression and craving scores.³
• Davis et al. 2017 and 2018 (University of Miami, Journal of Psychedelic Studies) — retrospective study of 88 former patients reporting reductions in withdrawal and abstinence rates that outperformed typical medication-assisted treatment benchmarks.⁵
• Malcolm et al. 2018 — meta-review concluded observational evidence is compelling but randomized data are essentially absent.
• Ona et al. 2023 (Drug and Alcohol Dependence) — systematic review of ibogaine and noribogaine for opioid use disorder confirmed the consistent anti-withdrawal signal and framed cardiac risk as the primary translational barrier.²
• Cherian et al. 2024 (Stanford MISTIC, Nature Medicine) — 30 special-operations veterans received the magnesium-ibogaine protocol at a Mexican clinic. PTSD symptoms fell 88%, depression fell 87%, and there were no serious cardiac adverse events.¹ The trial's target indication was TBI-related PTSD, not OUD, but it validated the safety protocol every serious OUD program now uses.

The Texas $50M IMPACT trial

The Texas IMPACT program is the largest public commitment to psychedelic research in US history. Governor Abbott signed Senate Bill 2308 on June 11, 2025, appropriating $50 million for FDA-authorized ibogaine clinical trials. On December 12, 2025, UTHealth Houston and UTMB Health were announced as co-leads of the IMPACT consortium, joining Baylor College of Medicine, UT Austin, Texas Tech, and Texas A&M.⁶

IMPACT is scoped to run parallel trials in three indications:

• Opioid use disorder — led by UTHealth Houston and UTMB Health.
• Traumatic brain injury — led by Baylor and UT Austin, building on the Stanford MISTIC design.
• Post-traumatic stress disorder — cross-institutional.

Enrollment is expected to open across 2026 through 2028. For opioid patients researching the no-cost FDA-IND pathway, the clinical-trial finder is the most reliable way to track when Texas IMPACT sites accept applications.

Cardiac safety: the magnesium-ibogaine paradigm

Cardiac risk is the defining safety issue for ibogaine treatment for heroin, oxycodone, and fentanyl dependence. Ibogaine prolongs the cardiac QT interval, which can trigger torsades de pointes — a lethal arrhythmia. The published literature includes at least 33 deaths associated with ibogaine exposure, almost all occurring in unregulated settings without pre-dose ECG screening or electrolyte correction.⁴

The magnesium-ibogaine paradigm is the field's answer. Intravenous magnesium raises the arrhythmia threshold and appears to buffer ibogaine's QT effect. Under this protocol, the Stanford MISTIC trial reported no clinically meaningful QT prolongation across 30 patients — a striking departure from the historical safety profile.

Proper cardiac screening at a credible clinic looks like this:

• 12-lead EKG before dosing, with physician review of the QTc interval.
• Exclusion of any patient with a baseline QTc above accepted thresholds or with a history of structural heart disease.
• Serum potassium and magnesium corrected to the mid-normal range before the session.
• Intravenous magnesium co-administration during dosing.
• Continuous cardiac monitoring for the first 12 hours, with ACLS-trained medical staff on site.
• At premium clinics, Holter monitoring extending into the second day.

A center that cannot describe all of the above in writing is not operating at the current standard of care. The best ibogaine treatment centers guide reviews seven programs by exactly these criteria.

How patients taper methadone or suboxone before treatment

Long-acting opioids block ibogaine's anti-addictive window. Standard protocol at every credible clinic requires patients on methadone or buprenorphine (suboxone) to switch to a short-acting opioid — morphine or hydrocodone — for two to four weeks before dosing, under medical supervision.

The pharmacokinetic reason matters. Methadone has a half-life of 24 to 36 hours and saturates the mu-opioid receptor far beyond the window in which noribogaine is active. If methadone is still bound when ibogaine is dosed, the anti-craving reset never occurs, and the patient risks a prolonged and severe post-session withdrawal instead. Buprenorphine's partial-agonist high receptor affinity produces a similar problem.

A practical detail most guides gloss over: reputable Mexican clinics require a documented 48-hour opioid-free period immediately before dosing, verified by urine drug screen at intake — not by patient self-report. Patients arriving under short-acting opioid influence are typically stabilized on site and dosed the following day. The ibogaine methadone taper and ibogaine suboxone taper protocols are the primary reason treatment programs run 7 to 10 days rather than the 3-day session most patients expect.

What treatment actually looks like

A typical ibogaine program for opioid addiction runs 7 to 10 days. The first two to three days are medical: intake screening, EKG, blood work, electrolyte correction, and the supervised taper transition if needed. Dosing day is usually day three or four, with the flood dose in the 10 to 20 mg/kg range delivered orally in the morning.

The acute experience runs 24 to 36 hours. The first 8 hours produce strong visionary content, often described as autobiographical and confrontational. The next 12 to 24 hours are a quieter reflective phase in which most patients are physically still and mentally processing. Continuous cardiac monitoring runs through this entire window. Withdrawal symptoms typically resolve within the first 12 hours — the effect most opioid patients travel for.

The remaining program days are integration: sleep recovery, gentle movement, meals, and structured conversations with an integration therapist. The post-session window — days three through seven after the experience — is characterized by unusually low craving and psychological openness. It is also when relapse risk re-emerges if structural supports are absent.

Cost and access

Full ibogaine programs at established Mexican and Costa Rican clinics run $5,000 to $15,000, including cardiac screening, accommodation, the session, and integration support. Premium medical-grade facilities with in-house cardiology and Holter monitoring run higher — up to $20,000 or more.

The main access pathways today:

• Mexico — Baja California (Rosarito, Tijuana — accessible from San Diego), Jalisco, and San José del Cabo host the largest cluster of established clinics.
• Costa Rica — regulated medical framework; smaller number of clinics but strong physician oversight.
• Portugal and the Netherlands — legal grey-zone medical use at a small number of European programs.
• FDA-IND clinical trials — the Texas IMPACT program, Stanford MISTIC extensions, and DemeRx IB-001 (Phase 1/2a for opioid withdrawal, conducted in the UK) are the no-cost pathways. See the clinical-trial finder and the retreat finder for country-specific listings.

For a reviewed comparison of seven established centers by cardiac screening standard, medical credentials, and pricing, see the best ibogaine treatment centers guide. For head-to-head substance comparisons, the ibogaine vs. ketamine guide covers the key differences for opioid patients weighing both options.

Ibogaine vs. methadone and buprenorphine MAT for opioid use disorder

Medication-assisted treatment (MAT) with methadone or buprenorphine remains the standard of care and has saved a great many lives. Ibogaine is not a replacement for MAT — it is a structurally different option with a different risk profile. The comparison below is meant to inform, not to argue for one path over another.

When patients choose ibogaine over MAT. Patients who have tried MAT and either could not tolerate the daily-medication lifestyle, could not taper off successfully, or want a defined end-point tend to be the population that travels for ibogaine. Patients with pre-existing cardiac conditions, patients who benefit from the daily structure MAT provides, and patients whose insurance covers extended MAT care are typically better served staying on the standard-of-care pathway. Neither path is universally superior — the question is fit.

When ibogaine is not the right fit

Ibogaine is not appropriate for every opioid patient. The following profiles should either avoid ibogaine or be excluded by any credible clinic:

• Any history of structural heart disease, prior arrhythmia, or baseline QTc above accepted thresholds.
• Uncontrolled hypertension or untreated coronary disease.
• Active stimulant use (cocaine, methamphetamine) — combined arrhythmia risk is unacceptable.
• Pregnancy or planned pregnancy in the immediate post-treatment window.
• Poly-drug patterns that keep QT-prolonging medications on board — many antipsychotics, some SSRIs, ondansetron, and macrolide antibiotics.
• Recent methadone use where a proper taper has not been completed.
• Severe untreated psychiatric conditions (active psychosis, uncontrolled bipolar) — ibogaine's 24 to 36 hour dissociative window is not a safe setting for these patients.

Bottom line

Ibogaine for opioid addiction is the strongest clinical signal in the psychedelic field, but it is also the indication with the most demanding safety infrastructure. The evidence supports the effect; the cardiac risk is real; the taper requirements are non-negotiable. Patients considering this path should confirm cardiac screening standards in writing, plan the methadone or suboxone taper with a supervising physician, and treat the post-session integration window as seriously as the session itself.

For opioid patients who want the FDA-authorized no-cost pathway, the Texas IMPACT program and DemeRx trials are the routes worth tracking. The clinical-trial finder lists current ibogaine studies and enrollment status. For patients going the international-clinic route, the best ibogaine treatment centers guide is the practical starting point. And for broader context on how ibogaine fits alongside other options, see the psychedelic therapy for addiction hub and the companion ibogaine for alcoholism guide.